Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study

Clinical Drug Investigation

Volumn 28, Issue 8, 2008, Pages 501-507

  Kauffman, Amy B ^a,b,c   Delate, Thomas ^a   Olson, Kari L ^a,b   Cymbala, Alicia A ^a   Hutka, Kara A ^a,b   Kasten, Sheila L ^a,b   Rasmussen, Jon R ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE   (United States)

Author keywords

Biomarkers; Cardiovascular disorders; Diabetes mellitus; Heart disorders

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PHARMACY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DISEASE ASSOCIATION; FEMALE; HEALTH SERVICE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVASCULARIZATION; RISK MANAGEMENT; SECONDARY PREVENTION; UNITED STATES; CARDIOVASCULAR DISEASE; LONGITUDINAL STUDY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CARDIOVASCULAR DISEASES; COLORADO; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 46749138725     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828080-00005     Document Type: Article

References (21)

1. American Heart Association. Heart disease and stroke statistics: 2008. Circulation 2008; 117: e25-e146
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005 [online]. Available from URL: http://www.diabetes.org/uedocuments/NationalDiabetesFactSheetRev.pdf [Accessed 2007 Oct 5]
3. Haffner S, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with or without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
4. Malmberg K, Yusuf S, Gerstein H, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q wave myocardial infarction: results of the Oasis Registry. Circulation. 2000; 102: 1014-9
5. Khaw K, Wareham N, Luben R, et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-8
6. Stettler C, Allemann S, Juni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 27-38
7. Khaw K, Wareham N, Bingham S, et al. Association of hemoglobin A1C with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk). Ann Intern Med 2004; 141: 413-20
8. Selvin E, Coresh J, Gold S, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes. Arch Intern Med 2005; 165: 1910-6
9. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 204; 141: 421-31
10. Corpus R, O'Neill W, Dixon S, et al. Relation of hemoglobin A1C to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol 2003; 92: 1282-6
11. Corpus R, George P, House J, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularizations in treated type II diabetic patients undergoing elective percutaneous coronary intervention. JACC 2004; 43: 8-14
12. Sandhoff B, Nies L, Olson K, et al. Clinical Pharmacy Cardiac Risk Service: guidelines and practices in a population approach to managing patients with coronary artery disease. Am J Health Syst Pharm 2007; 64: 77-84
13. Olson K, Rasmussen J, Sandhoff B, et al. A global and sustained approach to lipid management of 8,014 patients with coronary artery disease: the 5-year Colorado Kaiser Permanente Clinical Pharmacy Cardiac Risk Service (CPCRS) experience. Arch Intern Med 2005; 165: 49-54
14. Pradhan A, Rifai N, Buring J, et al. Hemoglobin A1C predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med 2007; 120: 720-7
15. Blake G, Pradhan A, Manson J, et al. Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 2004; 164: 757-61
16. De Vegt F, Dekker J, Ruhé H, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-31
17. Thanyasiri P, Celermajer D, Adams M. Predictors of long-term outcome following percutaneous coronary intervention in patients with type 2 diabetes mellitus. Coron Artery Dis 2006; 17: 131-8
18. Hadjadj S, Coisne D, Mauco G, et al. Prognostic value of admission plasma glucose and HbA1C in acute myocardial infarction. Diabet Med 2004; 21: 305-10
19. Goff D, Gerstein J, Ginsberg H, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 1i-20i
20. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i-33i
21. The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59